TABLE 1.
Baseline characteristics of NHPs included in the study
| VEH | BMS LD | BMS MD1 | BMS MD2 | BMS HD | API LD | API MD | API HD | DAB LD | DAB MD | DAB HD | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Group size | 8 | 5 | 6 | 6 | 6 | 4 | 4 | 4 | 3 | 3 | 3 |
| Sex | 5 M, 3 F | 1 M, 4 F | 3 M, 3 F | 2 M, 4 F | 2 M, 4 F | 4 F | 2 M, 2 F | 3 M, 1 F | 3 M | 3 M | 3 M |
| Age, y, mean (range) | 6.4 (5‐7.1) | 5 (4.4‐5.9) | 5 (4.1‐6.2) | 4.2 (3.8‐4.7) | 4.5 (3.4‐6.9) | 4.1 (3.8‐4.8) | 3.8 (3.2‐4.2) | 4.7 (4.4‐5.0) | 4.6 (4.0‐5.8) | 7.0 (5.9‐8.2) | 6.0 a |
| Body weight, kg, mean (range) | 5.9 (3.1‐8.7) | 3.9 (4.4‐5.9) | 4.9 (3.1‐8.5) | 4.1 (3.1‐5.5) | 4 (3.2‐4.7) | 3.3 (3.0‐3.9) | 3.9 (3.1‐4.9) | 5.9 (4.7‐6.7) | 7.4 (5.6‐9.8) | 7.8 (7.5‐8.4) | 8.0 (7.6‐8.4) |
VEH; BMS at 0.025 + 0.05 (LD), 0.05 + 0.1 (MD1), 0.102 + 0.2 (MD2), and 0.4 + 0.8 (HD) mg/kg+mg/kg/h i.v.; API at 0.024 + 0.036 (LD), 0.12 + 0.18 (MD), and 0.6 + 0.9 (HD) mg/kg+mg/kg/h i.v.; and DAB at 0.024 + 0.036 (LD), 0.12 + 0.18 (MD), and 0.6 + 0.9 (HD) mg/kg+mg/kg/h i.v.
Abbreviations: API, apixaban; BMS, BMS‐724296; DAB, dabigatran; HD, high dose; i.v., intravenous; LD, low dose; MD, medium dose; VEH, vehicle.
a
Age data were missing for two nonhuman primates.